/Hologic%2C%20Inc_%20logo%20outside%20building%20by-%20Tada%20Images%20via%20Shutterstock.jpg)
Valued at $16.5 billion by market cap, Hologic, Inc. (HOLX) is a global leader in the medical technology and diagnostics industry. Headquartered in Marlborough, Massachusetts, the company specializes in innovative solutions for critical markets, including women's health, diagnostics, and medical imaging.
Companies valued at over $10 billion are often categorized as “large-cap stocks,” a category Hologic fits through its significant market presence. Hologic’s commitment to innovation in medical technology, driven by cutting-edge advancements in diagnostics, imaging, and surgical solutions, reflects its focus on improving patient outcomes and addressing critical healthcare needs.
Hologic’s shares are down 14.1% from their 52-week high of $84.67, achieved on Aug. 9. Over the past three months, the stock has declined 9.2%, significantly underperforming the broader Dow Jones Industrials Average’s ($DOWI) 2.7% gains over the same time frame.
Over the past 52 weeks, HOLX stock returned 2.3% and gained marginally over the past six months. It notably underperformed the Dow, which increased by 10.7% over the past six months and 15.4% over the last year.
Hologic has exhibited bearish momentum, trading below its 50-day moving average since November and its 200-day moving average since December.
Shares of Hologic declined 5.9% following the release of its Q3 earnings on Nov. 4. Its adjusted EPS of $1.01 missed the $1.02 consensus estimate despite a 13.5% year-over-year increase. Revenue increased 4.5% year-over-year to $987.9 million but came below the forecast.
However, for fiscal 2025, Hologic projects revenue between $4.15 billion and $4.20 billion, representing 3% to 4% year-over-year growth. Adjusted EPS is estimated to be between $4.25 and $4.35, reflecting 4.2% to 6.6% annual growth.
Highlighting the contrast in performance, HOLX's competitor, Intuitive Surgical, Inc. (ISRG), has outperformed HOLX. ISRG has gained 59.7% over the past year.
Despite its recent underperformance, analysts maintain a cautiously optimistic outlook on HOLX. The stock has a consensus "Moderate Buy" rating from 18 analysts and has a mean price target of $89.19, which indicates a potential upside of 22.6% from its current level.
